MedTrace Logo

High Dose Omeprazole in Patients With Pancreatic Cancer

NCT04930991 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-08

No results posted yet for this study

Summary

The purpose of this study is to test the safety of high dose omeprazole and see what effects that it has on patients with exocrine pancreatic cancer.

Conditions

  • Exocrine Pancreatic Cancer

Interventions

DRUG

Omeprazole

Treatment will consist of Omeprazole 12-14 days prior to surgical therapy of pancreatectomy.

Sponsors & Collaborators

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Ajay Jain, MD · University of Oklahoma

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-07
Primary Completion
2026-09-30
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04930991 on ClinicalTrials.gov